Global Oncology Biomarker Market Report By Profiling Technology (Omic Technology, Imaging Technology, Immunoassays, And Cytogenetic-Based Tests), By Biomolecule (Genetic Biomarkers, Protein Biomarkers And Glycol-Biomarkers), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer And Others), By Application (Diagnostics, Drug Discovery And Development, Prognostics, Risk Assessment And Others) And By Regions - Industry Trends, Size, Share, Growth, Estimation And Forecast, 2018-2025
ID:VMR11210352
January 2019
Report Formats:

As per this study the Global Oncology Biomarker Market was valued USD 12.4 BN (by revenue) in 2018 and is anticipated to reach USD 28 BN by 2025 with a CAGR of 12.5%.

A biomarker is referred to as a traceable biomolecule, whose presence found in body fluids such as blood, serum, urine, and tumor fluid that indicates disease or an underlying condition such as cancer. Oncology biomarkers are the biomolecules that are secreted only by tumor cells that leads to diagnosis or prognosis of cancer. Oncology biomarker includes protein, muted genes, DNA, mRNA, and metabolites that aids in the diagnosis of cancer.
 
Market Dynamics
 
Growing count of the population suffering from various types of cancer has created demand of biomarkers leading to early diagnosis and prognosis of cancer. Increase funding by government for cancer diagnosis technique and treatment is fueling the market growth. Owing to a non-invasive method for cancer detection followed by increased cancer awareness is boosting the market growth. In spite of this advantage, high cost associated with diagnosis is restraining the market growth.
 
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of oncology biomarker.
 
Market Segmentation
 
The broad oncology biomarker market has been sub-grouped into profiling technology, biomolecule, cancer type, and application. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
 
By Profiling Technology

  • Omics Technology
    • Genomics
    • Proteomics
    • Other Omics Technologies
  • Imaging Technology
  • Immunoassays
  • Cytogenetic-Based Tests
 
By Biomolecule
  • Genetic Biomarkers
  • Protein Biomarkers
  • Glycol-Biomarkers
 
By Cancer Type
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Others
 
By Application
  • Diagnostics
  • Drug Discovery And Development
  • Prognostics
  • Risk Assessment
  • Others
 
Regional Analysis
 
Furthermore, the report comprises of the geographical segmentation, which mainly focuses on current and forecast demand for oncology biomarker in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
 
Europe Oncology Biomarker Market By Revenue (USD MN)
 
Europe Oncology Biomarker Market By Revenue
 
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the oncology biomarker market include Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Genomic Health, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Pfizer, Inc. and Qiagen N.V. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
 
 
METHODOLOGY:
 
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand. 

1. INTRODUCTION

  • Introduction To Oncology Biomarker
  • Report Description
    • Objectives Of The Study
    • Assumptions
  • Research Scope
  • Research Methodology
    • Data Source
 
2. EXECUTIVE SUMMARY
  • Market Highlight
  • Global Oncology Biomarker Market: Snapshot
 
3. MARKET ANALYSIS
  • Drivers
  • Restraints
  • Opportunities
  • Porter’s Five Forces Analysis
  • Value Chain Analysis
 
4. ONCOLOGY BIOMARKER MARKET ANALYSIS BY PROFILING TECHNOLOGY
  • Market In Omics Technology
    • Market In Genomics
    • Market In Proteomics
    • Market In Other Omics Technologies
  • Market In Imaging Technology
  • Market In Immunoassays
  • Market In Cytogenetic-Based Tests
 
5. ONCOLOGY BIOMARKER MARKET ANALYSIS BY BIOMOLECULE
  • Market In Genetic Biomarkers
  • Market In Protein Biomarkers
  • Market In Glycol-Biomarkers
 
6. ONCOLOGY BIOMARKER MARKET ANALYSIS BY CANCER TYPE
  • Market In Lung Cancer
  • Market In Breast Cancer
  • Market In Colorectal Cancer
  • Market In Prostate Cancer
  • Market In Stomach Cancer
  • Market In Others
 
7. ONCOLOGY BIOMARKER MARKET ANALYSIS BY APPLICATION
  • Market In Diagnostics
  • Market In Drug Discovery And Development
  • Market In Prognostics
  • Market In Risk Assessment
  • Market In Others
 
8. ONCOLOGY BIOMARKER MARKET ANALYSIS BY GEOGRAPHY
  • North America (NA)
    • North America Market Estimates
    • North America Market Estimates By Country
    • United States (U.S.) Market Estimates By Segments
    • Rest Of North America Market Estimates By Segments
  • Europe (EU)
    • Europe Market Estimates
    • Europe Market Estimates By Country
    • United Kingdom (UK) Market Estimates By Segments
    • Germany Market Estimates By Segments
    • France Market Estimates By Segments
    • Rest Of Europe Market Estimates By Segments
  • Asia Pacific (APAC)
    • Asia Pacific Market Estimates
    • Asia Pacific Market Estimates By Country  
    • China Market Estimates By Segments
    • Japan Market Estimates By Segments
    • India Market Estimates By Segments
    • Rest Of Asia Pacific Market Estimates By Segments  
  • Latin America (LA)   
    • Latin America Market Estimates
    • Latin America Market Estimates By Country
    • Brazil Market Estimates By Segments
    • Rest Of Latin America Market Estimates By Segments
  • Middle East And Africa (MEA)   
    • Middle East And Africa Market Estimates
    • Middle East And Africa Market Estimates By Country
    • Middle East Market Estimates By Segments
    • Africa Market Estimates By Segments
 
9. COMPETITIVE LANDSCAPE OF THE ONCOLOGY BIOMARKER COMPANIES
  • Market Competition
  • Partnerships/Collaborations/Agreements
  • Mergers And Acquisitions
  • New Product Launches
  • Other Developments
 
10. COMPANY PROFILES OF THE ONCOLOGY BIOMARKER INDUSTRY (Company Overview, Financial, Major Products & Recent Development)
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F.Hoffmann-La Roche Ltd.
  • Genomic Health, Inc.
  • GlaxoSmithKline plc
  • Novartis AG, Merck & Co., Inc.
  • Pfizer, Inc.
  • Qiagen N.V.
 
* Tentative TOC
 
LIST OF TABLES
 
Table 1.  Market Highlights Of Oncology Biomarker
Table 2.  Global Oncology Biomarker Market By Profiling Technology
Table 3.  Global Oncology Biomarker Market By Biomolecule
Table 4.  Global Oncology Biomarker Market By Cancer Type
Table 5.  Global Oncology Biomarker Market By Application
Table 6.  Global Oncology Biomarker Market By Geography
Table 7.  North America Oncology Biomarker Market
Table 8.  Europe Oncology Biomarker Market
Table 9.  Asia Pacific Oncology Biomarker Market
Table 10. Latin America Oncology Biomarker Market
Table 11. Middle East And Africa Oncology Biomarker Market 
Table 12. Partnership/Collaboration/Agreements
Table 13. Mergers And Acquisitions
Table 14. New Product Development
Table 15. Other Developments
  
LIST OF FIGURES
 
Fig. 1.     Market Segmentation Of Oncology Biomarker Market 
Fig. 2.     Top-Down Approach   
Fig. 3.     Bottom-Up Approach   
Fig. 4.     Market Highlights Of Oncology Biomarker
Fig. 5.     Porter’s Five Forces Analysis
Fig. 6.     Value Chain Analysis
Fig. 7.     Global Oncology Biomarker Market By Profiling Technology
Fig. 8.     Global Oncology Biomarker Market By Biomolecule
Fig. 9.     Global Oncology Biomarker Market By Cancer Type
Fig. 10.   Global Oncology Biomarker Market By Application
Fig. 11.   Global Oncology Biomarker Market By Geography
Fig. 12.   North America Oncology Biomarker Market
Fig. 13.   Europe Oncology Biomarker Market
Fig. 14.   Asia Pacific Oncology Biomarker Market
Fig. 15.   Latin America Oncology Biomarker Market
Fig. 16.   Middle East And Africa Oncology Biomarker Market
Fig. 17.   Market Share Of Oncology Biomarker Companies
Fig. 18.   Recent Developments In Oncology Biomarker Industry
 
 
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC. 

Objectives of Study

  • Define and measure the global market
  • Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
  • Analyze and identify major market trends along with the factors driving or inhibiting the market growth
  • Study the company profiles of the major market players with their market share
  • Analyze competitive developments

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

Client First Policy
Excellent Quality
Robust After Sales Support
24/7 Email Support

Clients

Testimonials